Nitrogen Bonded Directly To Ring Carbon Of The Seven-membered Hetero Ring Patents (Class 514/211.13)
-
Patent number: 8198268Abstract: Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment.Type: GrantFiled: October 23, 2009Date of Patent: June 12, 2012Assignee: Janssen Biotech, Inc.Inventors: Hector Guzman, Alexey Popov, Thomas J. L. Rammeloo, Julius Remenar, Jihad B. Saoud, Mark Tawa
-
Publication number: 20120129836Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.Type: ApplicationFiled: November 18, 2011Publication date: May 24, 2012Applicant: H. Lundbeck A/SInventors: Jan Kehler, Jacob Nielsen, Mauro Marigo, John Paul Kilburn, Morten Langgård
-
Publication number: 20120129835Abstract: Methods of preparing and using neural cells derived from human induced pluripotent stem cell (hiPSCs), particularly hiPSCs derived from subjects with schizophrenia are provided. The hiPSC-derived neural cells can be used to screen test compounds and to identify schizophrenia marker functions. The hiPSC-derived neural cells can be used to diagnose and/or assess the severity of schizophrenia in a subject. Further, may the hiPSC-derived neural cells from a subject be used as an in vitro system to identify the most effective candidate among existing drugs for that specific subject (i.e. personalized medicine).Type: ApplicationFiled: November 16, 2011Publication date: May 24, 2012Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Kristen Brennand, Fred H. Gage
-
Publication number: 20120129834Abstract: Methods are provided for the treatment and/or prophylaxis of Huntington's disease. In various embodiments the methods involve administration of one or more serotonin receptor antagonists. In certain embodiments the serotonin receptor antagonists include, but are not limited to loxapine, and/or a loxapine analogue, and/or cyproheptadine, and/or a cyproheptadine analogue (e.g., pizotifen).Type: ApplicationFiled: September 16, 2011Publication date: May 24, 2012Applicant: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: ROBERT HUGHES, LISA ELLERBY
-
Publication number: 20120122793Abstract: S-protected cysteine analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: PROMENTIS PHARMACEUTICALS, INC.Inventors: Edward M. Johnson, Daniel G. Lawton
-
Publication number: 20120122792Abstract: S-t-butyl protected cysteine di-peptide analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: PROMENTIS PHARMACEUTICALS, INC.Inventors: Edward M. Johnson, II, Daniel G. Lawton
-
Patent number: 8173637Abstract: A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.Type: GrantFiled: September 5, 2008Date of Patent: May 8, 2012Assignee: Handa Pharmaceuticals, LLCInventors: Fang-yu Liu, Zhi-qun Shen
-
Publication number: 20120108570Abstract: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.Type: ApplicationFiled: January 6, 2012Publication date: May 3, 2012Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Miodrag Radulovacki, David W. Carley
-
Publication number: 20120108545Abstract: Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: ApplicationFiled: May 19, 2010Publication date: May 3, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Lauren E. Woodard, David R. Levine, Deuk Kyu Moon, Bryan T. Mott
-
Patent number: 8168677Abstract: Method for therapeutic treatment of inflammatory bowel disease, including Crohn's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a retinoid as an active ingredient to treat the inflammatory bowel disease, the retinoid being selected from the group consisting of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid, 4-[(3,5-bis-trimethylsilylphenyl)carboxamido]benzoic acid, 4-[2,3-(2,5-dimethyl-2,5-hexano)dibenzo[b,f][1,4]thiazepin-11-yl]benzoic acid, and 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid.Type: GrantFiled: September 14, 2009Date of Patent: May 1, 2012Assignee: Kemphys Ltd.Inventors: Koichi Shudo, Hiroyuki Kagechika, Hiroshi Fukasawa, Tetsuro Matsuishi, Naoko Katsumura, Miwako Ishido
-
Patent number: 8163731Abstract: A method of reducing the concentration of a chemical or drug substance in the blood plasma that targets the same or similar receptors as the normal neurotransmitters in the central or peripheral nervous system includes titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together extends theType: GrantFiled: August 20, 2008Date of Patent: April 24, 2012Assignee: Rhodes TechnologiesInventors: Kenneth C. Slater, Brenda E. Richardson, Scott M. Connors, Wei-wei Chang
-
Patent number: 8158618Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.Type: GrantFiled: June 19, 2009Date of Patent: April 17, 2012Assignee: AstraZeneca ABInventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
-
Publication number: 20120087952Abstract: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.Type: ApplicationFiled: September 13, 2011Publication date: April 12, 2012Applicant: Civitas Therapeutics, Inc.Inventors: Raymond T. Bartus, Dwaine F. Emerich
-
Publication number: 20120077800Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.Type: ApplicationFiled: August 23, 2011Publication date: March 29, 2012Applicant: Alkermes, Inc.Inventors: Daniel Deaver, Mark Todtenkopf
-
Patent number: 8138169Abstract: Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.Type: GrantFiled: April 10, 2009Date of Patent: March 20, 2012Assignee: ComgenRx, Inc.Inventors: Bryan T. Oronsky, Neil C. Oronsky
-
Publication number: 20120035156Abstract: The present invention relates to a pharmaceutical combination of a glycine transporter inhibitor (GlyT1) and an atypical antipsychotic drug which may be used for the treatment of positive and negative symptoms of schizophrenia.Type: ApplicationFiled: August 1, 2011Publication date: February 9, 2012Inventors: Daniela Alberati, Jean-Luc Moreau, Joseph G. Wettstein
-
Patent number: 8101596Abstract: The invention relates to novel compounds and methods of using them for modulating sleep.Type: GrantFiled: March 25, 2009Date of Patent: January 24, 2012Assignee: Hypnion Inc.Inventors: Dale M. Edgar, David G. Hangauer, Michael Solomon
-
Patent number: 8101597Abstract: The present invention relates to novel and stable salt forms of quetiapine, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides novel acid addition salts of quetiapine wherein the acid counter ion is provided by an acid selected from the group consisting of benzene sulfonic acid, dibenzoyl-L-(+)-tartaric acid and di-p-toluoyl-L-(+)-tartaric acid. The present invention also provides novel polymorphic forms of quetiapine salts selected from the group consisting of quetiapine hydrobromide, quetiapine sulfate, quetiapine nitrate and quetiapine citrate.Type: GrantFiled: May 7, 2008Date of Patent: January 24, 2012Assignee: Actavis Group PTC EHFInventors: Girish Dixit, Anil Shahaji Khile, Jayesh Laljibhai Patel, Nitin Sharadchandra Pradhan, Jon Valgeirsson
-
Patent number: 8093237Abstract: The present invention relates to 11-(piperazin-1-yl)dibenzo[b,f][1,4 ]oxazapine compounds of the formula: where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD, autism, senile psychosis, psychotic dementia, L-DOPA induced psychosis, psychogenic polydipsia, psychotic symptoms of neurological disorders, sleep disorders.Type: GrantFiled: March 13, 2008Date of Patent: January 10, 2012Assignee: ARYx Therapeutics, Inc.Inventors: Cyrus Becker, Courtney Rubens, Jason Adams, Monica Palme, Pascal Druzgala
-
Publication number: 20120003330Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: May 31, 2011Publication date: January 5, 2012Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Chengzhi Zhang, Manoucherhr Shahbaz
-
Publication number: 20110319384Abstract: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and Anxiety Disorders and for treating one or more of the symptoms of these disorders.Type: ApplicationFiled: September 9, 2011Publication date: December 29, 2011Applicant: AstraZeneca ABInventors: Hans Eriksson, Martin Brecher, Rohini Chitra, Joan Shaw, Mårten Vågerö, Ellis Wilson
-
Publication number: 20110319383Abstract: The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed.Type: ApplicationFiled: November 16, 2007Publication date: December 29, 2011Applicant: ASTRAZENECA ABInventors: Daniel Brown, Donna Caster, Brian Clark, Sandra Hopkins, Jennifer Llewelyn, Lisa Martin, Elizabeth Meehan, Robert Timko, Husheng Yang
-
Publication number: 20110312938Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula (I) wherein R1, R2, R3, and RN are as defined herein. Compounds of Formula (I) are useful in the prevention and/or treatment of neurological and psychiatric disorder, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the disclosure and methods of treating the aforementioned conditions using such compounds.Type: ApplicationFiled: June 30, 2009Publication date: December 22, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Regina Graul, John Jeffrey Talley, Ara Mermerian
-
Publication number: 20110280938Abstract: The present invention relates to sustained release pharmaceutical composition of quetiapine, and process for preparing such composition. More particularly, it relates to sustained release pharmaceutical composition of quetiapine comprising a non gelling agents such as carrageenan and pharmaceutically acceptable excipients.Type: ApplicationFiled: January 4, 2010Publication date: November 17, 2011Applicant: TORRENT PHARMACEUTICALS LIMITEDInventors: Navin Ishwarlal Vaya, Narendra Dulichand Soni, Baxis Rameshchandra Joshi
-
Patent number: 8048876Abstract: The invention comprises a process for preparing quetiapine and/or its salts, including, quetiapine fumarate. The process generally comprises reacting dibenzothiazepinone (dibenzo[bf][1,4]thiazepin-11(10H)-one) with phosphorous oxychloride in the presence of triethylamine in an aromatic organic solvent such as toluene or, preferably, xylene at reflux temperature to obtain an aromatic hydrocarbon solution of 11-chloro-dibenzo[bf][1,4]thiazepine. Thereafter, the 11-chloro-dibenzo[bf][1,4]thiazepine is reacted with 2-(2-piperazin-1-ylethoxy)-ethanol to yield, following several processing steps, quetiapine. Compound I can then be further reacted with fumaric acid at elevated temperature to yield quetiapine fumarate. The resulting quetiapine fumarate obtained is suitable for use in pharmaceutical preparations.Type: GrantFiled: April 21, 2006Date of Patent: November 1, 2011Assignee: Medichem S.A.Inventors: Jordi Bosch I Lladó, Maria Carmen Burgarolas Montero, Iolanda Chamorro Gutiérrez
-
Patent number: 8044039Abstract: The present invention relates to a process for preparing and purifying crystalline quetiapine hemifumarate, which comprises preparing crystalline quetiapine hemifumarate via a crystalline salt, which is not a salt of fumaric acid.Type: GrantFiled: October 26, 2006Date of Patent: October 25, 2011Assignee: Fermion OyInventors: Arne Grumann, Soini Huhta, Petteri Rummakko, Viesturs Lusis
-
Patent number: 8044038Abstract: The present invention relates to a process for preparing crystalline quetiapine hemifumarate, which comprises crystallizing or re-crystallizing quetiapine hemifumarate from a mixture of water and a water soluble alcohol.Type: GrantFiled: September 28, 2006Date of Patent: October 25, 2011Assignee: Fermion OyInventors: Petteri Rummakko, Arne Grumann, Soini Huhta, Tuomas Koiranen
-
Publication number: 20110251175Abstract: The invention relates to methods for the treatment or prevention of substance use disorders.Type: ApplicationFiled: July 16, 2009Publication date: October 13, 2011Inventors: Nadia Rupniak, James F. White
-
Publication number: 20110251144Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: September 16, 2009Publication date: October 13, 2011Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Patent number: 8034805Abstract: A method for the preparation of salts of 2-[2-(4-dibenzo[b,fj[1,4]thiazepin-11-yl-1 -piperazinyl)ethoxy]ethanol (quetiapine) from the quetiapine base and the respective acid, wherein the salt is precipitated from a mixture of solvents, the mixture being either a mixture of an aromatic hydrocarbon and a ketone or ester, or that of an aromatic hydrocarbon, water and a ketone or ester. The salts of quetiapine are purified by partial crystallization, wherein only a part of the salt of quetiapine is dissolved in a C1 to C6 alcohol used.Type: GrantFiled: August 31, 2006Date of Patent: October 11, 2011Assignee: Farmak, A.S.Inventors: Pavel Hradil, Lubomir Kvapil, Roman Gabriel, Martin Grepl, Jan Novotny, Petr Slezar, Radek Melnicky
-
Publication number: 20110245231Abstract: The invention relates to novel drug substance for the treatment of alcohol dependence, pharmaceutical composition, medicament and method for treatment of dependence on using ethyl alcohol containing beverages.Type: ApplicationFiled: December 15, 2009Publication date: October 6, 2011Applicant: Alla Chem, LLCInventors: Andrey Alexandrovich Ivashchenko, Nikolay Filippovich Savchuk
-
Publication number: 20110244020Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.Type: ApplicationFiled: April 1, 2011Publication date: October 6, 2011Applicant: Alexza Pharmaceuticals, Inc.Inventors: Ron L. HALE, Craig C. Hodges, Peter M. Lloyd, Amy T. Lu, Daniel J. Myers, Joshua D. Rabinowitz, Martin J. Wensley, Jeffrey A. McKinney, Alejandro C. Zaffaroni
-
Publication number: 20110237568Abstract: 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine, compositions thereof, preparations thereof, formulations thereof, prodrugs thereof and pharmaceutical uses thereof.Type: ApplicationFiled: March 18, 2010Publication date: September 29, 2011Inventors: SIMON N. BLACK, SIMON D. BROADY, ALAN S. KIRSCHNER, JAMES A. OSBORN, STEWART D. JOLLY, DAN B. BROWN, DANIEL KOREY, KAREN B. MAIN, RICHARD J.R. CREEKMORE, JEAN M. SURIAN, VIVIAN Y. BI, PETER BERNSTEIN, JAMES B. CAMPBELL, GREG CHRISTOPH, SCOTT W. GRIMM, DAN WIDZOWSKI, JAMES HULSIZER, PHIL EDWARDS
-
Publication number: 20110237537Abstract: Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method.Type: ApplicationFiled: March 29, 2011Publication date: September 29, 2011Inventor: Jay L. Lombard
-
Publication number: 20110223207Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.Type: ApplicationFiled: March 9, 2011Publication date: September 15, 2011Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
-
Publication number: 20110206782Abstract: The present invention relates to new piperidine modulators of dopamine receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: February 15, 2011Publication date: August 25, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Chengzhi Zhang
-
Publication number: 20110206780Abstract: The present invention relates to new morphinan modulators of NMDA receptors, ?1 receptors, ?2 receptors, and/or ?3?4 nicotinic receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: January 5, 2011Publication date: August 25, 2011Applicant: Auspex Pharmaceuticals, Inc.Inventors: Thomas G. Gant, Sepehr Sarshar, Chengzhi Zhang
-
Patent number: 8003637Abstract: A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.Type: GrantFiled: March 28, 2011Date of Patent: August 23, 2011Assignee: Handa Pharmaceuticals, LLCInventors: Fang-yu Liu, Zhi-qun Shen
-
Publication number: 20110183963Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.Type: ApplicationFiled: December 22, 2010Publication date: July 28, 2011Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
-
Publication number: 20110165238Abstract: A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.Type: ApplicationFiled: March 28, 2011Publication date: July 7, 2011Applicant: HANDA PHARMACEUTICALS, LLC.Inventors: Fang-yu Liu, Zhi-qun Shen
-
Publication number: 20110151002Abstract: A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form.Type: ApplicationFiled: June 29, 2009Publication date: June 23, 2011Applicant: LUPIN LIMITEDInventors: Avinash Krishnaji Velhal, Sunil Anantrao Mirajkar, Virendra Ramkrupal Kuril, Vineeth Raghavan, Ninad Deshpanday
-
Publication number: 20110144088Abstract: A method of treating at least one symptom or condition associated with but not limited to: Sleep Disorders including but not limited to 1) Dyssomnia Disorders including but not limited to: a) Primary inomnia, b) Primary Hypersomnia, and c) narcolepsy; and 2) Parasomnias Disorders including but not limited to a) Nightmare Disorder, Sleep Terror Disorder and Sleepwalking Disorder, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.Type: ApplicationFiled: November 8, 2010Publication date: June 16, 2011Inventors: Patricia C. Davis, Jeffrey M. Goldstein, Scott W. Grimm, Helen R. Winter, Raymond F. Suckow
-
Publication number: 20110144089Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.Type: ApplicationFiled: November 15, 2010Publication date: June 16, 2011Applicant: AstraZeneca ABInventors: Patricia C. Davis, Jeffrey M. Goldstein, Scott W. Grimm, Helen R. Winter, Raymond F. Suckow
-
Publication number: 20110136742Abstract: The invention provides antidepressant prodrugs comprising an antidepressant conjugated to one or more amino acids. The invention also relates to pharmaceutical compositions comprising an antidepressant prodrug, and to methods of preparing and using the same.Type: ApplicationFiled: February 22, 2007Publication date: June 9, 2011Inventors: Travis Mickle, Wendy Hirschelman Severs
-
Publication number: 20110136785Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt.Type: ApplicationFiled: November 8, 2010Publication date: June 9, 2011Inventors: Patricia C. Davis, Jeffrey M. Goldstein, Scott W. Grimm, Helen R. Winter, Raymond F. Suckow
-
Publication number: 20110136786Abstract: Methods of treating mood disorders comprising administering an effective amount of 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions therefor.Type: ApplicationFiled: November 8, 2010Publication date: June 9, 2011Inventors: Patricia C. Davis, Jeffrey M. Goldstein, Scott W. Grimm, Helen R. Winter, Raymond F. Suckow
-
Publication number: 20110105468Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: August 18, 2010Publication date: May 5, 2011Inventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110105467Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: August 18, 2010Publication date: May 5, 2011Inventors: TIMOTHY L. RAMSEY, MARK D. BRENNAN
-
Publication number: 20110105466Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: November 4, 2009Publication date: May 5, 2011Inventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110105469Abstract: Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: November 3, 2010Publication date: May 5, 2011Applicant: Suregene, LLCInventors: Timothy L. Ramsey, Mark D. Brennan